| Date | Title | Description |
| 29.03.2021 | Cell-Easy strengthens executive team with two new highly experienced members | Jérôme Bédier joins as Chief Operating Officer and Guillaume Lay as Global Business Development Manager. |
| 08.03.2021 | Focus on Merieux Equity Partners and their upcoming fifth investment vehicle - Mérieux Participations 4 | This Fund will be dedicated to Growth & Buyout, with a target of € 500M. |
| 08.03.2021 | Focus on Merieux Equity Partners' upcoming fifth investment vehicle - Mérieux Participations 4 | The Fund will be dedicated to Growth & Buyout, with a target of € 500M.
(article in Les Echos) |
| 02.03.2021 | SERB completes acquisition of BTG Specialty Pharmaceuticals | This acquisition transforms the group into a global leader and a fully integrated specialty pharmaceutical platform. |
| 18.02.2021 | AcuSurgical raises €5.75 M in Series A financing, to advance its robotic ocular microsurgery platform | The company will use the proceeds of the Series A financing to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication, paving the way for future applications that are not within the reach o... |
| 12.01.2021 | MERIEUX EQUITY PARTNERS ACQUIRES MAJORITY STAKE IN PLANTEX, VIA ITS MERIEUX PARTICIPATIONS 3 VEHICLE | Plantex is a French manufacturer of high quality natural plant extracts for nutraceutical, dietary, animal nutritional and cosmetic purposes. |
| 21.12.2020 | ELSAN has entered into exclusive discussions with C2S Group with the aim of a merger | This operation would enable Elsan and C2S to become the number one private healthcare operator in France. |
| 10.12.2020 | Merieux Equity Partners invests in Laboratoires CTRS alongside the Management Team, via its Merieux Participations 3 vehicle. | CTRS is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs, with a particular focus on orphan diseases. |
| 08.12.2020 | Cell-Easy announces the completion of a financing round to accelerate its growth trajectory in the cell therapy sector, with Merieux Equity Partners as lead investor and reference shareholder | Cell-Easy is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development. |
| 30.11.2020 | BIOBEST acquires ownership of Beneficial Insectary Inc. of California | Beneficial Insectary Inc. is North America's largest independent producer of beneficial insects and mites. |
| 24.11.2020 | CEVA becomes first animal health company to be awarded "Animal Welfare-Friendly" certification by Brazil's dairy sector | Two products were approved by the Welfare Scheme - Velactis and Ketofen. |
| 19.11.2020 | SEQENS invests in new technologies and is committed to producing essential molecules to secure the supply chain of critical essential drugs substances at 5 of its industrial facilities | To carry out these projects, Seqens relies on the SEQENS’Lab, its R&D center, and on four of its APIs and pharmaceutical intermediates production sites and a total investment of €65 million. |
| 09.11.2020 | XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS | Gvoke® net sales grew 370% quarter over quarter to $9.4 million driven by launch of Gvoke HypoPen®. |
| 23.10.2020 | ProDigest and Biofortis announce an agreement for a global collaboration in the field of gastrointestinal research | This Agreement will enable a combination of the know-how in preclinical testing developed by ProDigest and the expertise in clinical trials and microbiome analysis of Biofortis. |
| 29.09.2020 | keepMED completes €13 M Series C financing round and advances towards regulatory clearance and market launch for keePAP in Europe and North America | keepMED has designed and developed keePAP® - a unique, responsive and personalized positive airway pressure (PAP) device for the treatment of Obstructive Sleep Apnea (OSA). |
| 29.09.2020 | CEVA BUILDS ON ITS PREVENTATIVE HEALTH STRATEGY WITH OPENING OF A NEW EUROPEAN REFERENCE FOR THE MANUFACTURE OF AUTOGENOUS VACCINES | This €8 million innovative project confirms Ceva’s commitment to improving preventative animal health and reducing the use of antibiotics. The addition to the existing Ceva Biovac site will further reinforce Ceva as the leading provider of ... |
| 28.08.2020 | SEQENS inaugurates an innovative HPAPI unit at its Villeneuve-La-Garenne plant, France | The site was inaugurated in the presence of Emmanuel Macron, President of the French Republic and Bruno Lemaire, Minister of the Economy, Finance and Recovery. |
| 10.08.2020 | XERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS | Gvoke® net sales were $2.0 million in Q2 2020. Gvoke PFS prescriptions grew 72% quarter over quarter. July availability of Gvoke HypoPen™ accelerates prescription growth. June capital raise significantly strengthens balance sheet. |
| 28.07.2020 | TARA Biosystems and VantAI Partner to Accelerate Cardiac Drug Development | VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration. The partnership will leverage TARA’s state-of-the-art in vitro human biology models and VantAI’s leading computational drug discovery capab... |
| 22.07.2020 | MRM Health appoints Dr. Werner Cautreels as Chairman and Dr. Nigel Horscroft as Chief Scientific Officer | Dr. Werner Cautreels, former CEO of Solvay Pharmaceuticals and Selecta Biosciences, has been appointed as Chairman of the Board and Dr. Nigel Horscroft, ex-Curevac and Pfizer, as Chief Scientific Officer. In addition, Dr. Ludo Haazen is joi... |
| 07.07.2020 | TARA Biosystems Report Study Results Demonstrating In Vitro Cardiac Biology Model Mimics Human Drug Response | Appearing in the Journal of Pharmacological and Toxicological Methods, these findings further support the use of TARA’s in vitro human cardiac models as a robust, translational platform for the evaluation of new medicines. The study was don... |
| 07.05.2020 | Mérieux Equity Partners and Korys announce the launch of OMX Europe Venture Fund, dedicated to Venture investment within the healthcare and nutrition sectors | The new investment platform in Venture Capital will support innovative companies in the healthcare and nutrition sectors, in Europe and North America. |
| 09.04.2020 | L'Entreprise des Possibles is Mobilizing Businesses to help the homeless in Lyon | First results and sollicitating sponsorships, partnerships and donations. |
| 19.03.2020 | Seqens is fully mobilized to guarantee the safety and health of its employees and also to contribute to supporting the Healthcare systems in the Covid-19 battle | Seqens will keep providing active ingredients and pharmaceutical intermediates such as paracetamol and keep developing antivirals and disinfecting solutions. |
| 19.03.2020 | Nutragroup is fully mobilized to first guarantee the safety and health of its employees, but also to contribute to supporting and enhancing the Health of the Human Beings against the Covid-19 threat | Nutragroup will keep delivering particular vitamins and immuno-stimulants to their customers (Food Supplement laboratories). |
| 12.03.2020 | CEVA Santé Animale returns to strong double-digit growth in 2019 and reveals plans to double sales by 2025 | Consolidated sales of the Ceva Group reached more than €1.2 billion in 2019. |
| 04.02.2020 | Ceva Santé Animale reorganizes its shareholding structure, welcoming new long-term partners alongside existing investors | - |
| 15.01.2020 | Twist Bioscience Selected as DNA Synthesis Provider for DNA Data Storage Project Under Intelligence Advanced Research Projects Activity (IARPA) Molecular Information Storage (MIST) Program | - |
| 13.01.2020 | Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer | Twist Bioscience also announces the appointment of Bill Banyai, Ph.D., as Senior Vice President of Advanced Development and General Manager of Data Storage. |
| 08.01.2020 | MERIEUX EQUITY PARTNERS SUCCESSFULLY COMPLETES THE FUNDRAISING OF MERIEUX PARTICIPATIONS 3 | Mérieux Equity Partners announces the closing of the fundraising for Mérieux Participations 3, new investment fund dedicated to Growth Capital and Buy-Out within the Healthcare and Nutrition sectors, oversubscribed at € 377 million. |
| 07.01.2020 | Genome editors begin lining up for Inscripta’s Onyx Digital Genome Engineering Platform | - |
| 06.01.2020 | XERIS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE IN-CLINIC STAGE OF A PHASE 2 STUDY OF ITS DEVELOPMENTAL RTU GLUCAGON | Results show that a mini dose of Ready-To-Use (RTU) Glucagon was adequate to maintain normal blood glucose levels in patients at risk of hypoglycemia (adults with Type 1 diabetes mellitus) during and after prolonged, moderate-to-intense aer... |
| 12.12.2019 | Protéus by Seqens launches SEQENZYM®, Enzyme Kits selected among an extensive library of Extremophile Strains for Fast Early Screening of Biocatalysts | The easy-to-use enzyme kits can accelerate screening of enzymes for molecules synthesis transformations by facilitating rapid assessment. |
| 11.12.2019 | Mérieux Equity Partners becomes reference shareholder of Addmedica | - |
| 11.12.2019 | Twist Bioscience and Pandion Therapeutics Expand Antibody Optimization Collaboration | Pandion is developing modular biologics and antibodies for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. |
| 11.12.2019 | Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results | Fiscal 2019 Revenues Increase 114% over Fiscal 2018 to $54.4M. Continued Strength in Synthetic Biology and NGS Businesses. Expect FY 2020 Revenues of $80M to $84M. |
| 10.12.2019 | XERIS PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IN-CLINIC STAGE OF THE PHASE 2 STUDY OF GLUCAGON | All subjects - at risk of postprandial hypoglycemia following bariatric surgery - successfully self-administered a mini dose of Ready-To-Use glucagon. Subcutaneous RTU glucagon is safe and well-tolerated. |
| 10.12.2019 | Inscripta Raises $125M in Series D Financing | New funding brings total amount raised to $259.5M and will be used to accelerate commercialization of revolutionary Digital Genome Engineering Platform. |
| 26.11.2019 | Merieux Equity Partners co-invests alongside IK Investment Partners in Mabtech | Mabtech's products are used by researchers and companies worldwide to study immune responses in cancer, allergy, infectious diseases and monitor vaccine trials. |
| 22.11.2019 | PhysioAssist announces that the multicentric MUCOSIM clinical trial is currently being recruited | The objective of this prospective randomized trial is to compare the efficacy and safety of the innovative Simeox technology in patients with cystic fibrosis compared to autogenous drainage. |
| 20.11.2019 | Twist Bioscience Promotes Patrick J. Finn to Chief Commercial Officer | Dr. Finn, Ph.D., previously served as senior vice president of commercial operations and will now be responsible for global commercialization of all products in addition to commercial development activities. |
| 08.11.2019 | Ivantis Announces 3 Year Results of Australian SPECTRUM Registry for Hydrus Microstent | SPECTRUM is a post market patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure outside the ... |
| 08.11.2019 | Twist Biopharma Implements Genedata Biologics to Advance Synthetic Biology-driven Antibody Discovery | Twist Biopharma, a division of Twist Bioscience, has adopted Genedata Biologics® to support their R&D innovation for biologics drug discovery services. In addition, Twist will use the Genedata platform to enable research in their develo... |
| 07.11.2019 | XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS | Gvoke™ (glucagon injection) pre-filled syringe is now available by prescription. MAA for ready-to-use glucagon is on track for submission to EMA by year-end and data from three Phase 2 studies expected by year-end. |
| 05.11.2019 | SGH Healthcaring unveils a new asthma spacer device, at CPHI 2019 | A revolutionary new design that improves drug administration and simplifies treatment delivery for better observance. |
| 30.10.2019 | Twist Bioscience to Provide Target Enrichment Products for MGI in Europe and Asia Pacific | Under the terms of the non-exclusive co-marketing agreement, MGI - a subsidiary of global genomics leader BGI Group - and Twist Bioscience are making Twist Bioscience catalog and custom products available on the MGI platform. |
| 30.10.2019 | SEQENS SPS increases the capacity of its isopropyl acetate unit only 3 years after the start of production | Based on an innovative process, with a reactive distillation and a high energy efficiency, this production unit in Roussillon (France) has been awarded by the Pierre Potier Price, promoting innovation for sustainable chemistry. |
| 25.10.2019 | Twist Bioscience Appoints Seasoned Life Sciences Industry Executive Nicolas M. Barthelemy to Board of Directors | Mr. Barthelemy brings extensive experience, both as an operational executive and board member, in the areas of biopharmaceutical, life science tools and molecular diagnostics. |
| 24.10.2019 | Biobest further strengthens their technical team by hiring Martin Zuijderwijk as their new Director of Technical Support Services | Mr Zuijderwijk will be responsible for the Technical Biocontrol Strategy. In addition, he and his team develop and manage the Biobest Academy, the knowledge platform for future IPM. |
| 10.10.2019 | Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent | Largest Single-Device Ophthalmic Registry Includes Nearly 3,000 Eyes with 700+ Stand-Alone Glaucoma Procedures. |
| 04.10.2019 | Focus on Mérieux Equity Partners in Private Equity Magazine | article in French |
| 01.10.2019 | Twist Bioscience Showcases New Innovation Lab at SynBioBeta 2019 | Innovation Lab is a program designed to translate customer needs into new, disruptive products facilitated by synthetic DNA at a scale previously unavailable. |
| 01.10.2019 | CEVA AND PROBIOGEN SIGN AN EXCLUSIVE LICENSE AGREEMENT TO PRODUCE VECTORISED POULTRY VACCINES USING AGE1.CR® PRODUCTION TECHNOLOGY | ProBioGen and Ceva have a long track record of producing innovative veterinary vaccine technologies from a number of different research and development programs. |
| 01.10.2019 | SuperSonic Imagine innovates in ultrasound with its new liver markers | This new diagnostic approach in ultrasound is made possible thanks to the new generation of UltraFast™ imaging. |
| 01.10.2019 | Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors | Mr. Thierer has a demonstrated track record of successful financial and operational strategy through more than 30 years of experience in the healthcare industry. |
| 01.10.2019 | Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering | The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. |
| 24.09.2019 | European Respiratory Society Study: Chronic Obstructive Pulmonary Disease (COPD) is four times more frequent with air pollution than with passive smoking | The WHO (2004) report is indisputable: chronic obstructive pulmonary disease will become the third leading cause of death in the world by 2030. |
| 19.09.2019 | XERIS PHARMACEUTICALS BEGINS DOSING PATIENTS IN A PHASE 2 CLINICAL TRIAL EVALUATING ITS NOVEL FIXED-RATIO CO-FORMULATION OF PRAMLINTIDE-INSULIN FOR DIABETES | The XeriSol™ technology allows for simultaneous concentration and stabilization of insulin and pramlintide, which are incompatible in aqueous (water-based) formulations. |
| 13.09.2019 | Amplitude, partner of the X-Pulse Project | The X-Pulse project aims to build a prototype of pre-clinical imaging system, based on x-ray sources generated by ultrafast lasers, specifically dedicated to the early detection of breast cancer. The first encouraging results were presented... |
| 10.09.2019 | CEVA PARTNERS WITH BIOTECON DIAGNOSTICS TO INTRODUCE A REAL-TIME TEST KIT TO FIGHT GROWING PROBLEM OF SALMONELLA ON PIG FARMS | The highly-sensitive test, using DNA, will detect and differentiate accurately between the vaccine strains and field strains of Salmonella Typhimurium (STM), the most important enzootic salmonella, within 24 hours. |
| 10.09.2019 | KERANOVA RAISES €24M IN SECOND ROUND OF FINANCING | Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser. |
| 10.09.2019 | XERIS PHARMACEUTICALS RECEIVES U.S. FDA APPROVAL FOR GVOKE™ (GLUCAGON) | GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for severe hypoglycemia. |
| 05.09.2019 | Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy | Dr. Lalonde has spent more than 25 years in research and development leadership, overseeing significant advances in methods for enzyme engineering and directed evolution. |
| 04.09.2019 | Seqens Cosmetics obtains Ecovadis’ gold certification for Corporate Social Responsibility | Seqens Cosmetics rank in the top 4% of companies assessed in the industry. |
| 29.08.2019 | Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts | Inscripta today announced the appointment of Deanna Church, Ph.D., Simon Cawley, Ph.D., and Nandini Krishnamurthy, Ph.D., three leading experts in bioinformatics, software engineering, and computational biology. |
| 29.07.2019 | Twist Bioscience launches Long Oligos to fuel drug development, DNA data storage and gene editing research | At up to 300 bases, or nucleotides, in length this is the longest commercial oligo offering by continuous chemical synthesis in the industry. |
| 03.07.2019 | CEVA COMPLETES ACQUISITION OF IDT VETERINARY BUSINESS ASSETS, MOVING CLOSER TO ITS 2020 OBJECTIVE OF 50:50 BIO-PHARMA SPLIT | Ceva and IDT have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva. |
| 21.06.2019 | SuperSonic Imagine announces that it has received a binding offer from the Hologic group to acquire 100% of the Company’s capital for a price of €1.50 per share | Hologic is planning to acquire a controlling stake of approximately 46% of the Company’s capital. |
| 18.06.2019 | Seqens is unveiling its main innovation and development centre near Paris | SEQENS'Lab is a 34,000 sqm science platform and centre of excellence for developing a totally unique package of R&D services. |
| 17.06.2019 | Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon | Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its stable liquid glucagon. |
| 31.05.2019 | Dr Jan Ohrstrom takes on Executive Leadership of BIOM'UP | Dr Ohrstrom has been Chairman of the Board of Directors since 2015. |
| 23.05.2019 | Twist Bioscience Strengthens Board With Semiconductor and Storage Expert Nelson C. Chan | Mr Chan, former CEO of Magellan, brings over 35 years of experience as both a director and operational executive in the technology and life sciences space. |
| 17.05.2019 | CEVA SANTE ANIMALE AND IDT BIOLOGIKA GMBH ANNOUNCE AGREEMENT | CEVA to acquire the IDT Animal Health business, expanding its global vaccine portfolio and boosting swine innovation. |
| 07.05.2019 | SGH Healthcaring - An original primary packaging range for nutraceuticals | Having recently acquired Eskiss Packaging, the group now offers a wide range of primary packagaing for the food supplement sector. |
| 02.05.2019 | Ivantis announces groundbreaking 3 year results from FDA clinical trial | First device in Minimally Invasive Glaucoma Surgical (MIGS) category to demonstrate significant long-term reduction of severe major surgeries for glaucoma patients. This is the first study of any kind showing a MIGS device achieving a stati... |
| 01.05.2019 | Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam | Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris' diazepam. Phase 2 study to be initiated in 2H2019. |
| 30.04.2019 | Inscripta Appoints Ron McGrath as Chief Financial Officer | Mr. McGrath has held leadership and financial roles for over 25 years in the biotechnology and information technology industries. |
| 08.04.2019 | Mérieux Equity Partners teams up with ICG to acquire leading Italian generic company, DOC Generici | DOC Generici is Italy’s largest independent generic pharmaceutical company. |
| 04.04.2019 | Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M | Continued support of existing investors will fund commercialization efforts, product launch later this year. |
| 28.03.2019 | Merieux Equity Partners to enter in exclusive negotiations for the sale of their stake in Amplitude Laser Group to L-GAM | Amplitude Laser Group has transformed itself into a global leader with a truly international footprint. |
| 25.03.2019 | Xeris Pharmaceuticals presents new Clinical and Economic Impact Data on its Developmental Ready-to-use Glucagon | Data from a Phase 2 study in congenital hyperinsulinism (CHI) reinforce the utility of Xeris’ ready-to-use, liquid-stable Glucagon. |
| 20.03.2019 | Seqens strengthens its cosmetics and healthcare offering with the acquisition of ID Bio and H2B | ID bio is a producer of natural ingredients for cosmetics and H2B is a manufacturer of fractionated blood products for in vitro diagnosis. |
| 15.03.2019 | LNA Santé acquires the Moulin Vert Rehabilitation Center | The Moulin Vert facility specializes in the treatment of respiratory diseases and heart disorders |
| 15.03.2019 | Xeris Pharmaceuticals doses first patient in Phase 2 trial evaluating its ready-to-use Glucagon to address Exercise-Induced Hypogycemia | Xeris has begun dosing Type 1 diabetes patients with its stable liquid Glucagon. |
| 14.03.2019 | Ivantis announces 24-month results of Landmark Clinical Trial | International multi-center study compares effectiveness of the Hydrus® Microstent to two Glaukos iStent® Trabecular Micro-Bypass stents in standalone glaucoma. |
| 14.03.2019 | Biobest's PMV®-01: First Vaccine against PepMV authorized in North America | PMV®-01 is the first plant vaccine against Pepino Mosaic Virus (PepMV) in tomato authorized by EPA and PMRA. |
| 13.03.2019 | Amplitude launches the Satsuma Display | Satsuma Display is the most compact air-cooled femtosecond laser on the market, offering 4 individual outputs. |
| 11.03.2019 | SGH Healthcaring acquires Eskiss Packaging and Dosapharm Laboratory | The French designer and manufacturer of innovative medical devices - formerly known as Stiplastics - continues to grow. |
| 25.01.2019 | SEQENS' R&D Center in Porcheville, France obtains its GMP Certificate | This confirms Porcheville's status as a center of excellence for the development and industrialization of complex molecules for the pharmaceutical industry. |
| 17.01.2019 | Benoit Chastaing joins Mérieux Equity Partners as Senior Partner | Benoit will foster the firm’s growth capital, MBO/LBO and majority investment activities. |
| 15.01.2019 | Mérieux Equity Partners has acquired a majority stake in Nutragroup | The acquisition was made via Mérieux Participations 3 - third generation fund dedicated to fast-growing companies in the health and nutrition sectors. |
| 24.12.2018 | Biobest and Australian company Bugs for Bugs team up through equity deal | BIOBEST expands in Australia |
| 21.12.2018 | Novacap becomes Seqens | SEQENS. A new name for a global leader in pharmaceutical synthesis and specialty ingredients. |
| 19.12.2018 | Inscripta's MAD7 CRISPR Enzyme is widely adopted by the Gene-Editing Community in the first year of release | Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research. |
| 31.10.2018 | Twist Bioscience completes a successful IPO on the Nasdaq | TWIST BIOSCIENCE writes a new chapter along its extraordinary growth trajectory |
| 24.10.2018 | TWIST Bioscience adds Ray Tabibiazar, M.D., as Senior Vice President, Corporate Development and Business Strategy | Dr Tabibiazar has also been appointed acting General Manager of the Division focused on biologics drug discovery. |
| 23.10.2018 | Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen | Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen. |
| 06.09.2018 | Biom'up completes sales organization to support US launch of HEMOBLASTTM Bellows | Biom'up completes sales organization to support US launch of HEMOBLASTTM Bellows |
| 06.09.2018 | Biom'up surpasses 200 surgeons | Biom'up surpasses 200 surgeons trained in the United States and Europe in anticipation of the launch of HEMOBLASTTM Bellows |
| 06.09.2018 | Mérieux Développement invests €20 million in Biobest, with the aim of establishing the company as a leader in natural solutions for pollination and crop protection through biological control | Mérieux Développement invests €20 million in Biobest, with the aim of establishing the company as a leader in natural solutions for pollination and crop protection through biological control. |
